TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hemorrhagic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhagic volume per unit area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intraocular pressure (IOP) after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of eyes with IOPs less than 18 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Need for antiglaucoma medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Quicker recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of side effects related to therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Interpeak amplitude (P1-N1) during hyperglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PHACO time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PHACO power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in self-rated health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in drug-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in negative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: injection cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distress reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in LBP intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in RMDQ scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Suture time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of cases of peritoneal tearing
Endpoint domain: Adverse events/effects
Primary endpoint: Surface hardness recovery (%SHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocabulary gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of kidney‐yang deficiency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm viability and motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Levels of serum testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: median scores from the initial written structure identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median scores from the second written exam at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average scores on the image acquisition practical at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: untoward event rate
Endpoint domain: Adverse events/effects
Primary endpoint: adverse events occurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: delays >15 minutes
Endpoint domain: Resource use
Primary endpoint: Urinary albumin/creatinine ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Indoor resting density of An. culicifacies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of treatment options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Median reduction in slough area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage area reduction of slough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthenia-fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: walking speed scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health quality of life subscale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: walking time per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength exercise time per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of moderate- or higher-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal rate of SEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median fat grading after cell saver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in fat weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentrations of phenolic metabolites (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-lives of elimination of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak concentration of metabolites (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fold increase upon vaccination for SY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asthma Quality of Life Scale (AQLQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: annual rate of moderate/severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of HSDD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual dysfunction adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CHF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: ER/outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: health distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in cariogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of minimum pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of maximum pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of positive margins after partial mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of second surgery for margin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HDRS(17) response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decreases in HDRS(17) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the frequency of asking clients about traumatic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with health service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systolic Blood Pressure (SBP) reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (DBP) reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Loss in lumbar BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss in distal forearm BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer assessment flexor synergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer assessment proximal upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height sd score gain at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any stage ROP or death
Endpoint domain: Mortality/survival
Primary endpoint: ROP requiring treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of antibodies to thrombin
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of overall IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobra rope score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peg transfer test completion speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global plasma irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biochemically validated cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative birth outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Time to virologic relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total ephedrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCSS (Venous Clinical Severity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D™
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for pharmacologic glucose control
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VTE (Venous Thromboembolism) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: postoperative hospitalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child generic HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: pain relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value for presence of ID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall diagnostic agreement for ID type III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trough forced expiratory volume in 1 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: transition dyspnea index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St George's Respiratory Questionnaire for COPD score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feed interruption days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of tumor necrosis factor‐α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction in disability scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the plasma concentration‐time curve (AUC0‐inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half‐life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tooth staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in whiteness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD improvement measured by Conners Abbreviated Symptom Questionnaire‐‐Teacher
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MUGA-defined cardio-toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dyspnea effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CPS knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSS installation skill scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1 beta concentration in wound exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour growth control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High adherence (≥80% of prescribed doses)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Likelihood of future daily gel use for HIV protection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean cumulative scores of the SF-36 QoL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surgical conditions rated as excellent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to walk and bypass the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: per episode antibiotic cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total episode cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of women using emergency contraceptive pills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary production reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Treatment-Resistant Depression (TRD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cost incurred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total nasal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TDE-related function in smokers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neck pain and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: algometric pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late hypoglycemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Growth of uterus and mammary glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Open infarct-related vessel (TIMI flow grade 2 or 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length (CoP parameters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of fast rhythm walking (TMWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDQ39 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of successful guidewire insertion on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of puncture attempts for internal jugular vein catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: brachial artery flow-mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of experiencing one or more serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of silent myocardial ischaemia (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protein delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for anti-emetic therapy
Endpoint domain: Adverse events/effects
Primary endpoint: measuring depressive and anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-TSH simulation T(4) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ECF impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse incidents
Endpoint domain: Adverse events/effects
Primary endpoint: overall response rate for abdominal pain and diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-A score response rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in mortality from lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Likelihood to volunteer to give blood
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Confidence in ability to avoid vasovagal reactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: peak postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for analgesic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of recovery and patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum sIL-2R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for conservative management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of prostate-specific antigen testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician decision-making control
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percentage of patients with pain score more than 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytomegalovirus disease development
Endpoint domain: Mortality/survival
Primary endpoint: Rates of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy in the treatment of PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response rates for CD4 + T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response rates for CD8 + T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rates for Env binding and neutralizing Ab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality-Adjusted Life Years (QALY) gain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual analogue scale scores of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum tHcy concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean percentage change in colitis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 3-year case fatality rates
Endpoint domain: Mortality/survival
Primary endpoint: stage at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 3-point MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated intraocular pressure (IOP) requiring surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Myoma number and size increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean endometrium width increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tube dislodgement rate
Endpoint domain: Adverse events/effects
Primary endpoint: Technical difficulties during gastrostomy placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MD index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSD index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCC thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modulation of specific miRs in colon tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED(95) of remifentanil for attenuating hypertensive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Antibiotic Prescription Rate (APR) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical and radiographic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio for relapse
Endpoint domain: Mortality/survival
Primary endpoint: Response to multidisciplinary obesity intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average compression depth during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality and long-term survival rate
Endpoint domain: Mortality/survival